The use of optical coherence tomography in neuromyelitis optica spectrum disorders

Česká verzia

Authors: J. Lízrová Preiningerová
Authors place of work: Neurologická klinika a Centrum klinických neurověd, 1. LF UK a VFN v Praze
Published in the journal: Cesk Slov Neurol N 2020; 83/116(supplementum 1): 37-43
doi: https://doi.org/10.14735/amcsnn2020S37

Summary

Optical coherence tomography (OCT) is an imaging technique that allows repeated non-invasive assessment of retinal layers. The report summarizes the use of OCT in the diagnostics of optic neuritis (ON) as one of the main characteristics of neuromyelitis optica spectrum disorder (NMOSD). ON in NMOSD leads to widespread destruction of ganglion cells and their fibers across the retina, resulting in a thinning of retinal nerve fiber layer (RNFL) in all peripapillary segments, as well as in a thinning of ganglion cell layer in macula. Unlike in NMOSD, ON in MS results in a predominant thinning of peripapillary RNFL in temporal segment. OCT helps differentiation between ON in the context of MS and NMOSD and thus contributes to early diagnosis of MS and NMOSD.

Keywords:

optical coherence tomography – neuromyelitis optica spectrum disorders

Zdroje

1. Monteiro ML, Fernandes DB, Apostolos-Pereira SL et al. Quantification of retinal neural loss in patients with neuromyelitis optica and multiple sclerosis with or without optic neuritis using Fourier-domain optical coherence tomography. Invest Ophthalmol Vis Sci 2012; 53 (7): 3959–3966. doi: 10.1167/iovs.11-9324.

2. Mealy MA, Wingerchuk DM, Greenberg BM et al. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 2012; 69 (9): 1176–1180. doi: 10.1001/archneurol.2012.314.

3. Sato DK, Callegaro D, Lana-Peixoto MA et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82 (6): 474–481. doi: 10.1212/WNL.0000000000000101.

4. Probstel AK, Rudolf G, Dornmair K et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation 2015; 12: 46. doi: 10.1186/s12974-015-0256-1.

5. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2015; 2 (1): e62. doi: 10.1212/NXI.0000 000000000062.

6. Merle H, Olindo S, Bonnan M et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 2007; 114 (4): 810–815. doi: 10.1016/j.ophtha.2006.06.060.

7. Ratchford JN, Quigg ME, Conger A et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 2009; 73 (4): 302–308. doi: 10.1212/WNL.0b013e3181af78b8.

8. Schneider E, Zimmermann H, Oberwahrenbrock T et al. Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis. PLoS One 2013; 8 (6): e66151. doi: 10.1371/journal.pone.0066151.

9. Park KA, Kim J, Oh SY. Analysis of spectral domain optical coherence tomography measurements in optic neuritis: differences in neuromyelitis optica, multiple sclerosis, isolated optic neuritis and normal healthy controls. Acta Ophthalmol 2014; 92 (1): e57–e65. doi: 10.1111/aos.12215.

10. Wingerchuk DM, Hogancamp WF, O‘Brien C et al. The clinical course of neuromyelitis optica (Devic‘s syndrome). Neurology 1999; 53 (5): 1107–1114. doi: 10.1212/wnl. 53.5.1107.

11. Matiello M, Lennon VA, Jacob A et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70 (23): 2197–2200. doi: 10.1212/01.wnl.0000303817.82134.da.

12. Jitprapaikulsan J, Chen JJ, Flanagan E et al. Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis. Ophthalmology 2018; 125 (10): 1628–1637. doi: 10.1016/j.ophtha.2018.03.041.

13. Sotirchos ES, Filippatou A, Fitzgerald KC et al. Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. Mult Scler 2019: 1352458519864928. doi: 10.1177/1352458519864928.

14. Sato DK, Nakashima I, Takahashi T et al. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology 2013; 80 (24): 2210–2216. doi: 10.1212/WNL.0b013e318296ea08.

15. de Seze J, Blanc F, Jeanjean L et al. Optical coherence tomography in neuromyelitis optica. Arch Neurol 2008; 65 (7): 920–923. doi: 10.1001/archneur.65.7.920.

16. Merle H, Olindo S, Donnio A et al. Retinal peripapillary nerve fiber layer thickness in neuromyelitis optica. Invest Ophthalmol Vis Sci 2008; 49 (10): 4412–4417. doi: 10.1167/iovs.08-1815.

17. Nytrova P, Kleinova J, Lizrova Preiningerova J et al. Neuromyelitis optica a poruchy jejího širšího spektra – retrospektivní analýza klinických a paraklinických nálezů. Cesk Slov Neurol N 2015; 78/111 (1): 72–77. doi: 10.14735/amcsnn201572.

18. Fernandes DB, Raza AS, Nogueira RG et al. Evaluation of inner retinal layers in patients with multiple sclerosis or neuromyelitis optica using optical coherence tomography. Ophthalmology 2013; 120 (2): 387–394. doi: 10.1016/j.ophtha.2012.07.066.

19. Oertel FC, Kuchling J, Zimmermann H et al. Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. Neurol Neuroimmunol Neuroinflamm 2017; 4 (3): e334. doi: 10.1212/NXI.0000000000000334.

20. Shen T, You Y, Arunachalam S et al. Differing structural and functional patterns of optic nerve damage in multiple sclerosis and neuromyelitis optica spectrum disorder. Ophthalmology 2019; 126 (3): 445–453. doi: 10.1016/j.ophtha.2018.06.022.

21. Wingerchuk DM, Banwell B, Bennett JL et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85 (2): 177–189. doi: 10.1212/WNL.0000000000001729.

22. Oertel FC, Havla J, Roca-Fernandez A et al. Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. J Neurol Neurosurg Psychiatry 2018; 89 (12): 1259–1265. doi: 10.1136/jnnp-2018-318382.

23. Zeka B, Lassmann H, Bradl M. Muller cells and retinal axons can be primary targets in experimental neuromyelitis optica spectrum disorder. Clin Exp Neuroimmunol 2017; 8 (Suppl 1): 3–7. doi: 10.1111/cen3.12345.

24. Felix CM, Levin MH, Verkman AS. Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G. J Neuroinflammation 2016; 13 (1): 275. doi: 10.1186/s12974-016-0746-9.

25. Hinson SR, Romero MF, Popescu BF et al. Molecular outcomes of neuromyelitis optica (NMO) -IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 2012; 109 (4): 1245–1250. doi: 10.1073/pnas.1109980108.

26. Levin MH, Bennett JL, Verkman AS. Optic neuritis in neuromyelitis optica. Prog Retin Eye Res 2013; 36: 159–171. doi: 10.1016/j.preteyeres.2013.03.001.

27. Bradl M, Reindl M, Lassmann H. Mechanisms for lesion localization in neuromyelitis optica spectrum disorders. Curr Opin Neurol 2018; 31 (3): 325–333. doi: 10.1097/WCO.0000000000000551.

28. Mader S, Kumpfel T, Meinl E. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases. Curr Opin Neurol 2020; 33 (3): 362–371. doi: 10.1097/WCO.0000000000000813.

29. Chen T, Lennon VA, Liu YU et al. Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion. J Clin Invest 2020; 130 (8): 4025–4038. J Clin Invest 2020; 130 (8): 4025–4038.